Your institution may have access to this item. Find your institution then sign in to continue.
Title
Safety and tolerability of dalcetrapib (RO4607381/JTT-705): results from a 48-week trial.
Authors
Stein, Evan A; Roth, Eli M; Rhyne, James M; Burgess, Tracy; Kallend, David; Robinson, Jennifer G
Abstract
Co-primary objectives were to evaluate dalcetrapib (JTT-705/RO4607381), which targets cholesteryl ester transfer protein (CETP), effects on high-density lipoprotein cholesterol (HDL-C) in participants with coronary heart disease or risk equivalents and to evaluate potential changes in mesenteric lymph nodes.
Publication
European heart journal, 2010, Vol 31, Issue 4, p480